Dogwood Therapeutics Q3 2026 Results: Net Loss of $4.88M, Loss Narrows
Dogwood Therapeutics reported a net loss of $21.4 million for the nine months ended September 30, 2026, which included a $9.2 million impairment charge related to IPR&D. The company ended the period with $4.9 million in cash and cash equivalents, down from $6.5 million at the end of 2025.
- Key figure
- Net loss $4.88M